NHS England has today published the following clinical commissioning policies and policy statements, in support of its role as the direct commissioner of specialised services:

• D05/P/f Clinical commissioning policy: Stereotactic radiosurgery/radiotherapy for glomus tumours
• D05/P/g Clinical commissioning policy: Radiosurgery/radiotherapy for cavernous venous malformations
• D05/PS/a Clinical commissioning policy statement: Stereotactic radiosurgery, radiotherapy for ocular melanoma and pituitary adenoma
• E03/PS (HSS)/a Clinical commissioning policy statement: Eculizumab for atypical haemolytic uraemic syndrome
• A13/PS/a Clinical commissioning policy statement: Rituximab for the treatment of systemic lupus erythematosus in adults
• B04/PS/a Clinical commissioning policy statement: Use of Plerixafor for stem cell mobilisation
• D05/P/e Clinical commissioning policy: Stereotactic radiosurgery/radiotherapy for meningioma
• B06/PS/a Clinical commissioning policy statement: Stribild for the treatment of HIV-1 infection in adult

Many of above documents have been superseded by newer versions. Please our Commissioning pages to find the latest versions.